Timothy J Pluard MD
Medical Director, Saint Luke’s Cancer Institute, Kansas City, MissouriTimothy J. Pluard, MD, is medical director at Saint Luke’s Cancer Institute And the Paul Koontz Endowed Chair of Breast Disease at the University of Missouri- KC School of Medicine. Under his leadership, Saint Luke’s has launched two new signature centers, offering a level of cancer expertise not found within 450 miles of Kansas City.
In 2016, Saint Luke’s Hospital launched its innovative Koontz Center for Advanced Breast Cancer, one of the few centers nationally, and the only in the Midwest, dedicated exclusively to the care of patients with metastatic breast cancer.
In 2017, Dr. Pluard led the creation of Saint Luke’s Center for Precision Oncology, the only center within a 450-mile radius that brings together experts in clinical oncology, tumor genomics, and computational biology. This unique multidisciplinary team has the expertise to identify the exact genomic alteration causing a patient’s tumor, and find the best possible treatment—even if it has never been used on that kind of cancer before.
Prior to joining Saint Luke’s, Dr. Pluard served as associate professor of medicine at Washington University in Saint Louis, and clinical director of the breast oncology program at Siteman Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center.
He has published extensively on new therapeutic approaches to breast cancer and the care of metastatic breast cancer patients.
Disclosures
Dr. Pluard reports the following disclosures: Consulting/Speaking Fees: Genentech, Pfizer, NovartisRecent Contributions to PracticeUpdate:
- Efficacy and Quality of Life Outcomes With Ribociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer
- Balixafortide Plus Eribulin for Metastatic Breast Cancer
- ESMO 2018: Overall Survival With Palbociclib Plus Fulvestrant
- ESMO 2018: Alpelisib Plus Fulvestrant for Hormone Receptor Positive Metastatic Breast Cancer
- Updates on CDK 4/6 Inhibitors in Metastatic Breast Cancer
- CXCR4 Antagonists and Breast Cancer
- ASCO 2018: Novel Ways to Improve Lung Cancer Screening
- Practice Impacting Data on Metastatic Breast Cancer From ASCO 2018
- Future Directions for Liquid Biopsies in Breast Cancer
- Sequencing Endocrine Therapies for ER+ Breast Cancer